{"id":11280,"date":"2020-12-01T14:22:46","date_gmt":"2020-12-01T08:52:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11280"},"modified":"2021-07-24T12:58:10","modified_gmt":"2021-07-24T07:28:10","slug":"pharma-happenings-for-dna-link-base10-takeda-advaxis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis","title":{"rendered":"BASE10 Collaboration; Advaxis Public offerings; Takeda&#8217;s CABOMETYX Japan approval; TheraPharm Acquisition"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f825048d90a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f825048d90a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\/#BASE10_Collaborates_with_DNA_Link_for_COVID-19_Antibody_Test_Research\" >BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\/#Advaxis_Announces_Closing_of_92_Million_Public_Offering\" >Advaxis Announces Closing of $9.2 Million Public Offering<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\/#Takeda_Receives_Approval_for_CABOMETYX_cabozantinib_Tablets_in_Japan\" >Takeda Receives Approval for CABOMETYX (cabozantinib) Tablets in Japan&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\/#Telix_Pharmaceuticals_Acquires_TheraPharm_GmbH\" >Telix Pharmaceuticals Acquires TheraPharm GmbH&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BASE10_Collaborates_with_DNA_Link_for_COVID-19_Antibody_Test_Research\"><\/span><strong>BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>US-based BASE10 Genetics<\/strong> and <strong>Korean firm DNA Link <\/strong>announced a collaboration on a research project to appraise the usability of the DNA Link&#8217;s antibody test, AccuFind COVID-19 IgG, in a healthcare setting.<\/p>\n\n\n\n<p>Currently, most antibody tests available in the market need the samples to be sent to the lab for further analysis, which adds to the time as well as cost. Thus, a test that can be done at the point of care and quickly provide the information to clinicians to move with the treatments will prove beneficial in many ways.&nbsp;<\/p>\n\n\n\n<p>The research is an important step towards evaluating and expanding access to antibody testing. The situation <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 <\/a>has put the whole world into has piqued the interest of the Pharma industry in antibody testing. In the scenario, DNA Link&#8217;s AccuFind has the potential to perform well in laboratory settings. It will be further investigated outside the laboratory settings to judge its efficiency as several factors may influence its functioning.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Advaxis_Announces_Closing_of_92_Million_Public_Offering\"><\/span><strong>Advaxis Announces Closing of $9.2 Million Public Offering<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A clinical-stage biotechnology company, <strong>Advaxis <\/strong>announced the closure of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the underwriters\u2019 option.<\/p>\n\n\n\n<p>Everything combined was sold at a public offering price of $0.30 per share for total gross proceeds of approximately $9.2 million before underwriting commissions and estimated expenses. The primary underwriter or lead coordinator in the offering was A.G.P.\/Alliance Global Partners.<\/p>\n\n\n\n<p>The net proceeds will help the company to fund its R&amp;D and expand its operations. The company is also going to make investments in its ADXS-HOT program, acquire or invest in other businesses, products, and technologies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Takeda_Receives_Approval_for_CABOMETYX_cabozantinib_Tablets_in_Japan\"><\/span><strong>Takeda Receives Approval for CABOMETYX (cabozantinib) Tablets in Japan&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Takeda has received approval from the Japanese Ministry of Health, Labor and Welfare to develop and commercialize CABOMETYX for the treatment of unresectable <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatocellular-carcinoma-market\" target=\"_blank\" rel=\"noreferrer noopener\">hepatocellular carcinoma (HCC).&nbsp;<\/a><\/p>\n\n\n\n<p>The approval is based on the results of the two clinical trials <strong>CELESTIAL <\/strong>(XL184-309), a global, randomized, placebo-controlled, double-blind phase 3 clinical trial, and <strong>Cabozantinib-2003<\/strong>, a phase 2 clinical trial conducted in Japan in patients with advanced HCC who had received prior systemic therapy.&nbsp;<\/p>\n\n\n\n<p>Cabozantinib is Exelixis\u2019 lead oncology medicine, which the company out-licensed to Takeda a few years back to handle commercialization and further clinical development in Japan. CABOMETYX&nbsp; is already approved in the U.S. and the EU for the treatment of patients with HCC who have been previously treated with sorafenib.&nbsp;&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Telix_Pharmaceuticals_Acquires_TheraPharm_GmbH\"><\/span><strong>Telix Pharmaceuticals Acquires TheraPharm GmbH&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Telix Pharmaceuticals signs an acquisition deal with Scintec Diagnostics GmbH (\u2018Scintec\u2019) to acquire TheraPharm GmbH (\u2018TheraPharm\u2019). TheraPharm, established in 2009, is a Swiss-German biotechnology company specializing in developing innovative diagnostic and therapeutic solutions in the field of hematology.<\/p>\n\n\n\n<p>Through the deal, Telix will get its hands on TheraPharm\u2019s vast portfolio of patents, technologies, production systems, clinical data, and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology.&nbsp;<\/p>\n\n\n\n<p>TheraPharm\u2019s antibody MTR technology, which works against CD66, a cell surface target highly expressed by neutrophils. The technology seems to offer a wide range of applications in the diagnosis and treatment of hematologic diseases (e.g.,<a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\" target=\"_blank\" rel=\"noreferrer noopener\"> blood cancers<\/a>), lymphoproliferative disorders, and immune-mediated diseases (e.g. <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\" target=\"_blank\" rel=\"noreferrer noopener\">lupus<\/a>, and multiple sclerosis).&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link&#8217;s antibody test, AccuFind COVID-19 IgG, in a healthcare setting. Currently, most antibody tests available in the market need the samples to be [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11291,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[638,16765,349,554,16766],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-11280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-antibody","tag-cabometyx","tag-latest-pharma-news","tag-takeda","tag-therapharm","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BASE10 antibody deal; CABOMETYX Japan approval; TheraPharm Acquisition<\/title>\n<meta name=\"description\" content=\"BASE10 antibody Collaboration with DNA Link; Takeda&#039;s CABOMETYX Japan approval; TheraPharm Acquisition; Advaxis Public offerings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BASE10 antibody deal; CABOMETYX Japan approval; TheraPharm Acquisition\" \/>\n<meta property=\"og:description\" content=\"BASE10 antibody Collaboration with DNA Link; Takeda&#039;s CABOMETYX Japan approval; TheraPharm Acquisition; Advaxis Public offerings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-01T08:52:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BASE10 antibody deal; CABOMETYX Japan approval; TheraPharm Acquisition","description":"BASE10 antibody Collaboration with DNA Link; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition; Advaxis Public offerings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis","og_locale":"en_US","og_type":"article","og_title":"BASE10 antibody deal; CABOMETYX Japan approval; TheraPharm Acquisition","og_description":"BASE10 antibody Collaboration with DNA Link; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition; Advaxis Public offerings","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-12-01T08:52:46+00:00","article_modified_time":"2021-07-24T07:28:10+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis","name":"BASE10 antibody deal; CABOMETYX Japan approval; TheraPharm Acquisition","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis.jpg","datePublished":"2020-12-01T08:52:46+00:00","dateModified":"2021-07-24T07:28:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"BASE10 antibody Collaboration with DNA Link; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition; Advaxis Public offerings","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-dna-link-base10-takeda-advaxis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis.jpg","width":772,"height":482,"caption":"pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/01142141\/pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CABOMETYX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TheraPharm<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody<\/span>","<span class=\"advgb-post-tax-term\">CABOMETYX<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">TheraPharm<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 1, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 1, 2020 2:22 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11280"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11280\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11291"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11280"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11280"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}